The urgent need to recover MHC class I in cancers for effective immunotherapy
about
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Monitoring of the Immune Dysfunction in Cancer PatientsT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous MelanomaPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.NLRC5, a promising new entry in tumor immunology.Challenges faced when identifying patients for combination immunotherapy.NLRC5/CITA: A Key Player in Cancer Immune Surveillance.Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.Rejection versus escape: the tumor MHC dilemma.The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Tuning cancer fate: the unremitting role of host immunity.Introduction: MHC/KIR and governance of specificity.Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.Targetless T cells in cancer immunotherapy.Improving radiotherapy in cancer treatment: Promises and challenges.Guidelines for the use of flow cytometry and cell sorting in immunological studies.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer.Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.Natural killer cell education in human health and disease.The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma.Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.The evolving understanding of immunoediting and the clinical impact of immune escape.Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients.Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.
P2860
Q27691330-E5C9BEA3-CDB0-49F7-935E-8D6EF410307AQ28072712-5F3C0F06-5EA3-407D-8D26-0CF3487449CEQ30832820-F23A0B0E-8DA8-4674-BB26-DD5DCBA0C491Q33741471-586EFB7B-957C-48B5-96EC-10C70BB506DAQ33839204-28E21D19-2CE4-4F2F-A8FC-A70E4DD370BBQ37108366-8F02430D-55BC-4FAF-A833-66C00889B2A8Q38638046-BA95A1C0-741B-4430-B128-C58FFE678146Q38656067-FA27E7D7-574E-4B6E-9DEE-E29A26484AC2Q38699774-FDB950A5-10C5-4526-A78C-51E4B6D58068Q38962024-B3D50681-F164-4008-AEB3-06C34A9DFE16Q39063943-572EA8D5-B46F-4058-9087-0370D30D7CB2Q39164068-7939347A-41B2-40BA-8238-8EA0668F7D70Q39210287-478B40C9-AFFA-4B32-B022-8C81597742B5Q39239026-D2013189-3193-456A-B139-6CD396F96C03Q39427560-FF07D4DA-BD81-4A64-A6F8-DAB0DB7459A8Q39429911-8874153E-45EE-4D22-ACD8-3377E1D230F8Q40152125-80E5C30B-3577-439D-ACD5-91F9F566509EQ40322821-EAA08FFC-A964-41AD-9FF1-C5F0081E3DD0Q41899048-06ED089A-EA73-477A-8395-5018D1CF16DFQ41918189-49EFDB2F-0BD2-4F77-AC06-8DD9794063EEQ41928232-3F32DCF4-AFB6-4C8F-AE43-FAD867E1AAE0Q41975457-1A7FBD11-C0F5-4BB7-8962-B0340CB75846Q42056165-E25FE965-6D6D-4CAD-A111-90B35719B588Q42365255-0063F43F-306B-4882-9E09-7EBEF46972F4Q42511974-158E4843-C0E1-4902-8301-CDF98A1B38BEQ47377609-E2CFA0C3-E0B4-4B8D-BF31-A549E326BD3EQ47438128-5FD52465-D75E-4031-A62C-28C92D729B79Q48058780-2303F191-4E98-4AB4-B76F-C1A535BF2AFFQ49296790-8E364C84-7F7A-47D0-8D74-80C02D31C008Q50054492-F0638A70-24E4-416B-98A1-922BABEC0F7BQ50137212-4BD1AF84-0363-4546-93AA-FFF47C9496F7Q51360609-0F2FFE86-1242-4DD3-A66D-7791C00B03FDQ51626800-7126B655-ED59-4A08-837F-A136F4520772Q52597557-05418127-9B29-4FAA-BBC2-A10A96BABD77Q52683991-9C9D1C60-6E48-428A-806C-3DA8996BB512Q53083279-8E1A90A7-2D09-445D-8DC2-3966CEC70EA3Q55301251-51DF9173-0647-4108-8589-A6D3743CCEAFQ55364385-1BCC0D6C-FF18-456E-9AD0-502590F13367Q55405564-33CD217E-6E5B-4980-8528-9E4EA2D27354Q55424304-33B93CC5-1683-4E60-81F7-87311CDF1956
P2860
The urgent need to recover MHC class I in cancers for effective immunotherapy
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The urgent need to recover MHC class I in cancers for effective immunotherapy
@ast
The urgent need to recover MHC class I in cancers for effective immunotherapy
@en
The urgent need to recover MHC class I in cancers for effective immunotherapy
@nl
type
label
The urgent need to recover MHC class I in cancers for effective immunotherapy
@ast
The urgent need to recover MHC class I in cancers for effective immunotherapy
@en
The urgent need to recover MHC class I in cancers for effective immunotherapy
@nl
prefLabel
The urgent need to recover MHC class I in cancers for effective immunotherapy
@ast
The urgent need to recover MHC class I in cancers for effective immunotherapy
@en
The urgent need to recover MHC class I in cancers for effective immunotherapy
@nl
P2093
P2860
P921
P3181
P1476
The urgent need to recover MHC class I in cancers for effective immunotherapy
@en
P2093
Elien M Doorduijn
Federico Garrido
Natalia Aptsiauri
P2860
P3181
P356
10.1016/J.COI.2015.12.007
P407
P5008
P577
2016-01-18T00:00:00Z